<DOC>
	<DOCNO>NCT00778921</DOCNO>
	<brief_summary>This study ass safety efficacy combination aliskiren/amlodipine patient hypertension adequately control amlodipine alone .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Combination Aliskiren/Amlodipine Patients With Hypertension Not Adequately Responding Amlodipine Alone</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Newly diagnose patient patient treated hypertension within 4 week prior Visit 1 must msDBP ≥ 95 mmHg &lt; 110 mmHg Visits 1 2 Patients treated hypertension within 4 week prior Visit 1 must msDBP ≥ 90 mmHg &lt; 110 mmHg Visit 2 All patient must msDBP ≥ 90 mmHg &lt; 110 mmHg Visit 5 ( randomization ) Severe hypertension Pregnant nursing ( lactate ) woman Premenopausal woman take accepted form birth control Serum potassium ≥ 5.3 mEq/L ( mmol/L ) Visit 1 History cardiovascular condition Uncontrolled Type 1 Type 2 diabetes mellitus Hypersensitivity renin inhibitor , calcium channel blocker , drug similar chemical structure Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Non-responder Amlodipine</keyword>
</DOC>